CannaPharmaRX delays Q3 report; revenue falls to $138K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CannaPharmaRX, Inc. (CPMD) said its Form 10-Q for the quarter ended September 30, 2026, was delayed because it needed more time to obtain and compile required information, a delay it said could not be eliminated without unreasonable effort or expense. It said it will file no later than the fifth calendar day following the prescribed due date.
For the three months ended September 30, 2026, revenue was $137,705 versus $656,606 in 2025, and gross loss was $277,782 versus $373,707. Net income was $645,416 versus a $1,477,811 net loss, primarily reflecting a $1,728,677 non-cash gain on the derivative conversion feature. For the nine months ended September 30, 2026, revenue was $1,041,385 versus $1,223,533, gross loss was $693,142 versus $1,367,918, and net loss was $1,645,647 versus $3,581,863. The lower nine-month net loss primarily reflected lower gross loss and a $1,930,000 other expense in 2025 that did not recur.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly net income was $645,416, versus a $1,477,811 net loss in 2025.
- Moderate pointNine-month net loss narrowed to $1,645,647 from $3,581,863 in 2025.
Negative
- Moderate pointQuarterly revenue was $137,705, versus $656,606 in 2025.
- Moderate pointNine-month revenue was $1,041,385, versus $1,223,533 in 2025.
Key Figures
Key Terms
derivative conversion feature financial
fair value financial
inventory write-downs financial
Rule 12b-25 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will CannaPharmaRX (CPMD) file its delayed September 2026 10-Q?
What were CannaPharmaRX (CPMD)'s third-quarter 2026 results?
AI-generated analysis. How Rhea-AI works. Not financial advice.